GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (NAS:GLMD) » Definitions » Accumulated other comprehensive income (loss)

GLMD (Galmed Pharmaceuticals) Accumulated other comprehensive income (loss) : $-0.42 Mil (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Galmed Pharmaceuticals Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Galmed Pharmaceuticals's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2024 was $-0.42 Mil.

Galmed Pharmaceuticals's quarterly Accumulated other comprehensive income (loss) increased from Jun. 2024 ($-0.44 Mil) to Sep. 2024 ($-0.34 Mil) but then declined from Sep. 2024 ($-0.34 Mil) to Dec. 2024 ($-0.42 Mil).

Galmed Pharmaceuticals's annual Accumulated other comprehensive income (loss) increased from Dec. 2022 ($-0.75 Mil) to Dec. 2023 ($-0.45 Mil) and increased from Dec. 2023 ($-0.45 Mil) to Dec. 2024 ($-0.42 Mil).

Galmed Pharmaceuticals Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Galmed Pharmaceuticals's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galmed Pharmaceuticals Accumulated other comprehensive income (loss) Chart

Galmed Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 -0.17 -0.75 -0.45 -0.42

Galmed Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.45 -0.46 -0.44 -0.34 -0.42

Galmed Pharmaceuticals Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Galmed Pharmaceuticals Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Galmed Pharmaceuticals's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Galmed Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (NAS:GLMD) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
LIXT ARTL ENVB MTNB PKTX TTNP NBY VIVS NCNA PALI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
16 Abba Hillel Road, Ramat Gan, ISR, 5250608
Website
https://www.galmedpharma.com
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.